Ribonucleotide reductases (RNRs) catalyze the conversion of nucleotides to deoxynucleotides in all organisms. The class I RNRs are composed of two subunits, ␣ and ␤, with proposed quaternary structures of ␣2␤2, ␣6␤2, or ␣6␤6, depending on the organism. The ␣ subunits bind the nucleoside diphosphate substrates and the dNTP/ATP allosteric effectors that govern specificity and turnover. The ␤2 subunit houses the diferric Y • (1 radical per ␤2) cofactor that is required to initiate nucleotide reduction. 2,2-Difluoro-2-deoxycytidine (F2C) is presently used clinically in a variety of cancer treatments and the 5-diphosphorylated F2C (F2CDP) is a potent inhibitor of RNRs. The studies with [1-3 H]-F2CDP and [5-3 H]-F2CDP have established that F2CDP is a substoichiometric mechanism based inhibitor (0.5 eq F2CDP/␣) of both the Escherichia coli and the human RNRs in the presence of reductant. Inactivation is caused by covalent labeling of RNR by the sugar of F2CDP (0.5 eq/␣) and is accompanied by release of 0.5 eq cytosine/␣. Inactivation also results in loss of 40% of ␤2 activity. Studies using size exclusion chromatography reveal that in the E. coli RNR, an ␣2␤2 tight complex is generated subsequent to enzyme inactivation by F2CDP, whereas in the human RNR, an ␣6␤6 tight complex is generated. Isolation of these complexes establishes that the weak interactions of the subunits in the absence of nucleotides are substantially increased in the presence of F2CDP and ATP. This information and the proposed asymmetry between the interactions of ␣n␤n provide an explanation for complete inactivation of RNR with substoichiometric amounts of F2CDP. G emcitabine, or 2Ј,2Ј-difluoro-2Ј-deoxycytidine (F 2 C), is a drug that is used clinically in the treatment of advanced pancreatic cancer and non-small cell lung carcinomas (1-3). In humans, F 2 C enters the cell via CNT-type or ENT-type transporters (4-6) and must be phosphorylated to exhibit its cytotoxicity. The monophosphate of F 2 C (F 2 CMP) is generated by deoxycytidine kinase (7) and is rapidly phosphorylated to the di-and triphosphates (F 2 CDP and F 2 CTP) (8, 9). Diphosphorylated F 2 C (F 2 CDP) is an irreversible inhibitor of ribonucleotide reductase (RNR) (10-13), and F 2 CTP functions as a chain terminator in the DNA polymerase reaction (14, 15). Differentially phosphorylated states of gemzar can also interfere with other enzymes involved in nucleotide metabolism. The mechanisms of cytotoxicity of F 2 C depend on the phosphorylated state of the inhibitor and are likely to be cell specific and multifactoral. Our recent synthesis of [1Ј-3 H]-F 2 CDP has provided the required tool to investigate the mechanism by which this molecule inactivates RNRs. Studies reported herein provide a previously unrecognized approach for RNR inhibition, one in which the mechanism based inhibitor (F 2 CDP) enhances the interactions between the two subunits of RNR preventing nucleotide reduction despite substoichiometric labeling.
G
emcitabine, or 2Ј,2Ј-difluoro-2Ј-deoxycytidine (F 2 C), is a drug that is used clinically in the treatment of advanced pancreatic cancer and non-small cell lung carcinomas (1) (2) (3) . In humans, F 2 C enters the cell via CNT-type or ENT-type transporters (4-6) and must be phosphorylated to exhibit its cytotoxicity. The monophosphate of F 2 C (F 2 CMP) is generated by deoxycytidine kinase (7) and is rapidly phosphorylated to the di-and triphosphates (F 2 CDP and F 2 CTP) (8, 9) . Diphosphorylated F 2 C (F 2 CDP) is an irreversible inhibitor of ribonucleotide reductase (RNR) (10) (11) (12) (13) , and F 2 CTP functions as a chain terminator in the DNA polymerase reaction (14, 15) . Differentially phosphorylated states of gemzar can also interfere with other enzymes involved in nucleotide metabolism. The mechanisms of cytotoxicity of F 2 C depend on the phosphorylated state of the inhibitor and are likely to be cell specific and multifactoral. Our recent synthesis of [1Ј-3 H]-F 2 CDP has provided the required tool to investigate the mechanism by which this molecule inactivates RNRs. Studies reported herein provide a previously unrecognized approach for RNR inhibition, one in which the mechanism based inhibitor (F 2 CDP) enhances the interactions between the two subunits of RNR preventing nucleotide reduction despite substoichiometric labeling.
RNRs catalyze the conversion on nucleoside di(tri)phosphates to deoxynucleoside di(tri)phosphates in all organisms and are the predominant control point for abundance and ratios of dNTPs pools required for the initiation and elongation processes catalyzed by DNA polymerases (16, 17) . The class I RNRs are composed of two types of subunits, ␣ and ␤. The quaternary structure of ␣ is nucleotide-and organism-dependent. It can be a monomer, dimer, tetramer, or hexamer (16, 18) . ␤ is a homodimer that houses the diferric-tyrosyl radical (Y • ) required for initiating nucleotide reduction on ␣. Current evidence suggests that there is one Y
• and 2 di-iron clusters/␤2 (19, 20) . The interactions between ␣ and ␤ are weak (K d of 0.2 M) in the absence of nucleotide (21) . In prokaryotic systems ␣ and ␤ are both homodimers. The active Escherichia coli RNR is thought to be an ␣2␤2 complex (22, 23) . The ␣ oligomeric state of the mouse RNR has been the best characterized eukaryotic RNR to date. In the absence of nucleotides, ␣ is a monomer. It dimerizes in the presence of allosteric effectors (dATP, TTP, dGTP, and ATP) (18) . In addition, the millimolar levels of ATP found intracellularly cause ␣ to oligomerize to a hexamer (␣6). ␤ is a homodimer (␤2). The quaternary structure of eukaryotic RNRs is still being actively investigated. The complex responsible for RNR activity has been proposed by Cooperman and coworkers (18) to be ␣2␤2, ␣6␤2, or ␣6␤6 on the basis of a variety of physical biochemical and kinetic studies. Recent gas-phase electrophoretic-mobility macromolecule analysis studies have suggested that the mouse quaternary structure is ␣6␤2 (24). Studying subunit interactions has been difficult by conventional methods because of ␣'s nucleotide-dependent aggregation state and the weak binding of ␣ and ␤, which is also nucleotide-dependent (21) . Determination of apparent molecular masses of the active RNR complexes requires nucleotides in the analysis buffer, and thus protein detection by UV spectroscopy is obscured (18, 23) .
A number of years ago, we reported on the inactivation of E. coli RNR by F 2 CDP (11, 12) . We showed that 1 eq of F 2 CDP per E. coli RNR, presumably ␣ 2 ␤ 2 , in the presence of reductants, thioredoxin (TR) and TR reductase or DTT, is sufficient for enzyme inactivation and that the inactivation is accompanied by release of 2 fluoride ions and one cytosine (12) . We also demonstrated that the mode of inhibition changed in the absence of reductants. Thus, as with all nucleotide mechanism based inhibitors of RNRs studied in detail, multiple modes of inactivation are involved in the inhibition process (Scheme 1). Purification of the ␣ and ␤ Subunits of Human RNR. The clones for ␣ and ␤ were obtained from the Y. Yen laboratory (City of Hope National Medical Center, Duarte, CA). Mutations in the genes were corrected to the sequence reported in the National Center for Biotechnology Information (NCBI) database (27, 28) , and the N terminus of each protein was reengineered to maintain the (His) 6 tag and to reduce the length of the intervening linker before the start of the gene to 10 aa. The proteins were purified to Ϸ90% homogeneity based on SDS/PAGE, using Ni affinity chromatography.
␤2 as isolated is a dimer in the apo form and was reconstituted by following the protocol we have developed for reconstitution of the E. coli ␤2 (29) . The resulting protein had 0.8 tyrosyl radicals/␤2 and a specific activity of 1,089 nmol/min/mg in the presence of a 7-fold excess of ␣. ␣ was difficult to work with because of its low solubility. However, its specific activity in the presence of a 7-fold excess of ␤ was 462 nmol/min/mg. These results contrast with previous reports in the literature of 75 nmol/min/mg and 158 nmol/min/mg for ␤ and 6.8 nmol/min/mg for ␣ (30, 31) . The basis for the activity differences are not understood, but are likely related to the complexity of the assay as we articulated in detail in ref. 32 . CDP, 0.19 and 0.08 eq were detected in the absence or presence of denaturant, respectively. These results establish that there is 1 eq of the sugar from F 2 CDP covalently bound to the enzyme and that most of the cytosine has been released. In addition, under these conditions, 40% of the tyrosyl radical is lost similar to our previous studies (12) . These results, in conjunction with the time-dependent inactivation studies, establish that substoichiometric amounts of F 2 CDP completely inactivate the E. coli RNR.
A similar set of experiments has been carried out on the human RNR. Time-dependent inactivation studies in which the inactivation mixture contained 0.5, 1.0, or 5.0 eq of F 2 CDP/␣ reveal that 0.5 eq of F 2 CDP/␣ results in complete loss of RNR activity (Fig. 1) . The instability of the ␤2 radical requires that a control in the absence of F 2 CDP be carried out and used to correct the data observed in its presence. The weak interaction between ␣ and ␤ of RNR allow assays of the subunit activity individually (21, 32) . Thus, the inactivation mixture was assayed for activity of ␣ (␤) in the presence of a 7-fold excess of ␤ (␣). Under these conditions, ␣ is 100% inactive. In contrast to expectations, ␤ retained 60-70% of its activity [supporting information (SI) Fig. 4 ], suggesting that the excess ␣ is capable of facilitating subunit dissociation. The results of these experiments have interesting implications in recovering RNR activity in vivo subsequent to its inactivation by F 2 CDP and will be discussed subsequently.
Studies Cytosine Release by Human RNR. The inactivation studies suggested that covalent modification is accompanied by cytosine release. To test this hypothesis, 2 eq of [5- 3 H] F 2 CDPs were incubated with ␣2␤2. Subsequent to inactivation the nucleotides were recovered by ultrafiltration and analyzed by HPLC. The analysis revealed 1 eq of cytosine and 1 eq of F 2 CDP. These results parallel those reported for inactivation of E. coli RNR (12) and support the model that inactivation can be achieved with substoichiometric amounts of F 2 CDP.
Subunit Interactions of E. coli RNR in the Presence of F2CDP. The active form of E. coli RNR is thought to be a 1:1 mixture of ␣2 and ␤2, although there is only one Y
• per ␤2, suggesting the active RNR complex is asymmetric. One way to achieve complete inactivation of ␣2␤2 with 1 F 2 CDP is that once chemistry has occurred in the active site of the first ␣, it precludes chemistry from occurring in the active site of the second ␣. This chemistry further leads to a tight complex between the two subunits preventing recycling of the unmodified ␣. To test this model, the inactivation mixture and a number of controls (including one with a mixture of ␣, ␤, and ATP) were examined by using SEC on a Superose 12 FPLC column. All elution buffers contained either 0.5 mM ATP or 100 M TTP previously shown to enhance ␣2 formation and more recently to enhance ␣2␤2 interactions.
The results of SEC analysis of RNR inactivated with F 2 CDP/ ATP, with ATP in the elution buffer, are summarized in Fig. 2 A-C and Table 2 . Fig. 2 A reveals a single protein peak. Fractions collected through the protein peak were analyzed by scintillation counting and by SDS/PAGE. The former revealed 0.9 labels per ␣2␤2 (Fig. 2 A) . The SDS/PAGE analysis (Fig. 2B ) revealed the presence of ␣ and ␤. Their relative ratios were determined in each fraction by comparison with standard curves made with known concentrations of ␣ and ␤ (Fig. 2B , standard curves not shown) and found to be Ϸ1:1 (Fig. 2C) .
A control SEC analysis in the absence of F 2 CDP, with ATP in the elution buffer reveals separation of ␣2 and ␤2 (Fig. 2 D and E) . Analysis of the ratio of ␣:␤ supports this conclusion (Fig. 2F ). The analysis in Fig. 2 suggests that a tight complex between subunits is unique to the presence of F 2 CDP.
Further experiments were carried out to assess the resolution of the SEC method and to obtain information about the relative molecular masses of the observed protein peaks. The behavior of the individual subunits and complex were examined. In the absence of nucleotides, ␣ migrates as a mixture of monomer and dimer with apparent molecular masses of 105 and 143 kDa (Table 2) , respectively. The apparent molecular masses are obtained by comparison of the retention times of the eluting proteins with retention times of known molecular mass standards (SI Fig. 5) . With ATP or TTP in the running buffer, ␣ now migrates as a dimer (␣2) of 174 kDa (Table 2 and SI Fig. 5 ). When RNR is inactivated by [1Ј-3 H] F 2 CDP/ATP and chromatographed with ATP in the running buffer, the protein has an apparent molecular mass of 277 kDa ( Fig.  2 A and SI Fig. 5 ). The SEC analysis presented in Fig. 2 A-C, the stability of the complex during the inactivation reaction and the subsequent 25 min chromatogratography, and the apparent molecular mass suggests that the active form of RNR is ␣2␤2 and that the interaction between the subunits has dramatically increased relative to the non-nucleotide bound forms (Table 2) .
Subunit Interactions of Human RNR in the Presence of F2CDP.
A similar set of experiments has been carried out with the human RNR. The Cooperman laboratory has demonstrated that in contrast with the prokaryotic RNRs, the active mouse RNR can be ␣2␤2, ␣6␤2, and ␣6␤6 depending on the concentration of ATP (18) . Recent studies using gas phase electrophoretic mobility macromolecule analysis have suggested that the active form of hRNR is ␣6␤2 (24). Biacore studies and kinetic studies demonstrate that the interactions between ␣ and ␤ in the absence of nucleotides, as in the prokaryotic case, are weak (K d ϭ 0.2 M) (21). Anticipated differences in the aggregation state of active RNR relative to the E. coli RNR caused us to switch to a Superdex 200 column for molecular mass analysis in the presence and absence of F 2 CDP in addition to ATP. The results of incubation of either 0.5 or 1 eq of [1Ј-3 H] F 2 CDP/ATP by SEC with ATP in the elution buffer are shown in Fig. 3 A and B and are summarized in Table 2 . Fractions were collected through the protein peak and analyzed by scintillation counting and by SDS/ PAGE (Fig. 3B) . In the former case, analysis gave 0.8 radiolabels/ ␣2. SDS/PAGE revealed the presence of both ␣ and ␤. The relative ratio of ␣:␤ of 1:1 was established by using standard curves made from ␣ and ␤ (SI Fig. 6 ).
Experiments were also carried out to assess the resolution of the SEC method and to obtain information about the relative molecular masses of the observed protein peaks. ␤2 migrates with an apparent molecular mass of 108 kDa (calculated 94.1 kDa; SI Fig.  7) . ␣ in the absence of nucleotides migrates as the expected monomer, whereas in the presence of TTP, it migrates as a dimer of 189 kDa (SI Fig. 7) . The retention time of the protein peak eluted from the RNR inactivated with F 2 CDP/ATP and with ATP in the elution buffer, relative to molecular mass standards reveals an apparent molecular mass of 872 kDa (SI Fig. 7 ). The 1:1 ratio of ␣:␤, the radiolabeling of the complex, and the apparent molecular mass in comparison with the expected mass of 834 kDa for ␣6␤6, 646 kDa for ␣6␤2, and 278 kDa for ␣2␤2, suggest that the active form of the human RNR is ␣6␤6 and that the subunits are tightly interacting. The results, as in the case of the E. coli RNR, provide an explanation for complete RNR inactivation with substoichiometric amounts of F 2 CDP. Inactivation of class I RNRs by F 2 CDP thus provides another paradigm for inhibitor design of this protein: increasing the subunit affinity.
A number of additional features in the chromatogram in Fig. 3A , peaks II and III, require comment. Two proteins copurify with ␣ and can be seen on SDS/PAGE with subunit molecular masses of 74 kDa and 65 kDa. The protein from peak II was isolated, sequenced and identified as an E. coli protein Arna, which exists as a hexamer in its native state (33) . The identity of peak III has not been determined, but SDS/PAGE analysis reveals it is not associated with RNR. Efforts to further purify ␣ via peptide and dATP affinity chromatography and several different anion exchange methods failed, because ␣ is not very soluble and is prone to aggregation. Recovery of ␣ and radiolabel from the column was 82%. The difference in the intensity of proteins in peak II and III (Fig. 3A) relative to SDS/PAGE is not understood.
Discussion
Many 2Ј-substituted-2Ј-deoxynucleotides have been shown to be potent mechanism based inhibitors of RNRs because the initial experiments in 1976 (34) . Detailed studies on 2Ј-fluoro, 2Ј-chloro and 2Ј-azido derivatives have provided the basis for a general mechanism of inhibition by these substrate analogs (Scheme 1) (35, 36 , N 3 Ϫ , or their conjugate acids) results in formation of intermediate A, which then partitions into two pathways depending on whether the 2Ј-radical is reduced by the top face thiol or a bottom face thiol. In the former case, the inactivation is caused by formation of a 3Ј-ketodeoxynucleotide which dissociates from the active site and decomposes to generate the nucleic acid base, pyrophosphate, and a furanone. The furanone then alkylates ␣ resulting in its inactivation. In the case of bottom face reduction, in addition to generating the 3Ј-ketodeoxynucleotide that eventually inactivates ␣ from solution through the furanone, the Y
• in ␤ remains reduced, thus ␤ also becomes inactivated. Most 2Ј-substituted deoxynucleotides inhibit class I RNRs by a combination of these pathways.
Studies presented herein suggest an additional mechanism by which 2Ј-substituted nucleotides may inactivate RNR. Gemzar has two fluorines at C2Ј. Both are lost during inactivation, at least in the case of the E. coli and Lactobacillus leichmannii RNRs, which have thus far been examined (12, 13) . In addition, with [1Ј-3 H] F 2 CDP inactivation is accompanied by 0.5 eq of sugar labeling from F 2 C/␣, Ϸ20-40% of tyrosyl radical loss and 100% loss of RNR activity. The mechanisms by which F 2 CDP inactivate the E. coli and human RNRs, thus, must occur by multiple pathways as previously observed with other 2Ј-substituted nucleotides. Furthermore, all pathways result in covalent labeling with the sugar of F 2 CDP and loss of cytosine. The details of the inactivation mechanism are complex and are not yet understood.
The observation of substoichiometric amounts of nucleotide resulting in complete RNR inactivation, at face value, seems difficult to understand. An explanation for the unusual stoichiometry is provided by the analysis of the RNR quaternary structure. In the case of the E. coli RNR, SEC reveals a tight ␣2␤2 complex (Fig. 2 A-C) when it is inactivated by F 2 CDP. A control in the absence of F 2 CDP reveals that ␣2 separates from ␤2 by the same chromatographic analysis (Fig. 2 D-F) . In retrospect, we have previously seen this type of behavior with another substoichiometric mechanism based inhibitor: 2Ј-azido-2Ј-deoxynucleotides, N 3 NDP (19, 37, 38) . During a 2-min incubation of RNR with [5Ј-3 H] N 3 NDPs, Ͼ90% of RNR activity is lost, 50% of Y
• is lost, and 0.7 eq radiolabel are associated with RNR. Protein denaturation, however, resulted in radiolabel release suggesting it is noncovalently bound or covalently bound in an unstable structure. In contrast with F 2 CDP, activity of ␣ with N 3 UDP is recovered to 50% and complete inactivation over 30 min is associated with 100% loss of Y • . Thus, although the subunits must be tightly associated initially to account for Ͼ90% loss of activity with just 50% loss of *The HPLC trace indicates multiple species. Gaussian fits to the peak shape, using Origin software, Version 6.1, gave the peak retention times. † Elution buffer contains 0.5 mM ATP. Fractions were collected through the protein peak and were analyzed by 10% SDS/PAGE as summarized in Fig. 2 A-F and Fig. 3 . ‡ Peak I, apparent mass 872 kDa (␣6␤6, 834 kDa) based on standard curve ( SI Fig. 6 ); Peak II: ArnA, apparent mass 484 kDa (hexamer of ArnA is 446 kDa); Peak III, subunit molecular mass 65 kDa based on SDS/PAGE. • , further chemistry associated with nucleotide allows subunit weakening and dissociation. An SEC experiment similar to the one described in Fig. 2 provides no evidence for an ␣2␤2 complex (SI Fig. 8 ). The unique chemistry associated with the different inhibitors thus can dramatically effect subunit interactions.
Inactivation of the human RNR, at least in the presence of reductant, mirrors the observations made with the E. coli RNR. One major difference, however, involves the quaternary structure of the human RNR. Our SEC studies have provided direct evidence in support of an active ␣6␤6 complex. This result contrasts with previous proposals of active ␣2␤2 and with the recent mass spectrometric studies suggesting that ␣6␤2 is the active form of RNR (24). Our results support the importance of the ␣6 form of the large subunit, first proposed by Cooperman's laboratory (18) . The SEC results also suggest that inactivation is the result of tight complex formation between the subunits that can occur even in the presence of substoichiometric amounts of nucleotide. At odds with this interpretation are the activity assays for each subunit in the presence of an excess of the second subunit. If a tight complex were present subsequent to inactivation, one would have expected that ␣ and ␤ would be 100% inactive. Although this was the case for ␣ (SI Fig. 4 ), ␤2 retains 60% of its activity. These results are very intriguing and provide us with additional insight about subunit interaction. The recovery of ␤2 activity requires that excess ␣ can form a transient ternary complex with ␣6␤6 and liberate ␤2, which has retained some of its Y
• and is thus active. This proposal is supported by a recent structure of a complex of the ␣2␤2 from E. coli where only one of the two ␤s interacts with ␣ (39). Thus, one could propose that binding of ␣ to the unattached ␤ of ␤2 could facilitate ␣2 release. In the case of the inactivated ␣␣*␤2 complex assayed with excess ␣ (␣* ϭ covalently labeled ␣), this mechanism would result in release of ␣␣* and formation of active ␣2␤2. Because there is only one [ 3 H]-label per ␣2, one would have expected the unlabeled monomer to be also active in the presence of excess ␤, but this is not the case. Thus, this result provides strong support for asymmetry within the ␣2 (␣6); that is, modification of one ␣ precludes activity of the other. The results suggest that if the cell was able to increase the amount of ␣, then active RNR could be recovered. Interestingly resistance in a number of cell lines has identified elevated ␣ levels (40) (41) (42) . F 2 CDP is unique with respect to the well characterized 2Ј-substituted nucleotide mechanism based inhibitors, in that in addition to labeling ␣ and loss of Y
• on ␤, inactivation is the result of tight subunit association.
Summary. RNR is inactivated by 0.5 eq of F 2 CDP/␣, as a consequence of altering the affinity of its two subunits and generating an asymmetric interaction within this complex. Recent studies using ␣ and ␤ substituted site specifically with unnatural amino acids have also been interpreted to suggest an asymmetry within the active RNR complex (19, 20) . Our results suggest that the paradigm of a 1:1 symmetrical complex between the two subunits of RNR must be re-evaluated. They further suggest a novel mode of inactivation of RNR. Expression Plasmids for Human ␣ and ␤ in E. coli. Sequencing of the ␣ and ␤ genes in phRRM1 and phRRM2, respectively, revealed a number of mutations relative to the sequences reported in the NCBI database (27, 28) . In the ␣ gene, nucleotide C521 was mutated to a T, resulting in a Val to Ala substitution. At residue 1763, C was changed to T, resulting in an Ile to Thr substitution. In the gene for ␤, A650 was changed to G, resulting in the conversion of a Lys to Arg. These mutations were corrected by site-directed mutagenesis, using the QuikChange Kit by Stratagene. In addition the N-terminal tags of each protein were reengineered to minimize the number of additional residues. The NdeI digestion site in ␣ was silenced. Both ␣ and ␤ genes were digested with NdeI and NotI and ligated into the NdeI-NotI sites of pET-28a (Novagen) to produce (His) 6 -␣ and (His) 6 -␤ containing a MGSSHHHHHHS-SGLVPRGSH-N terminus. All constructs were verified by sequencing at the MIT biopolymers laboratory.
Materials and Methods
Expression and Purification of Human ␣ and ␤. phRRM1 and phRRM2 were transformed into E. coli BL21 (DE3) (Stratagene) and plated on LB agar plates with 50 g/ml kanamycin, and a single colony was chosen for growth. For isolation of ␤, an overnight culture (40 ml) grown to saturation was diluted into 2 liters of LB containing 50 g/ml kanamycin and grown at 37°C to an OD 600 of 0.7-0.9. Isopropyl-1-thio-␤-D-galactopyranoside (1 mM) was then added, and the cells were grown for an additional 6 h at 30°C. For growth of ␣, an overnight culture (40 ml) was grown from a single colony at 37°C and transferred to 2 liters of LB and grown at 37°C. Isopropyl-1-thio-␤-D-galactopyranoside (1 mM) was added at an OD 600 of 0.7-0.9, and the cells were grown overnight at 25°C. The isolation of ␤2 and ␣ were carried out by the following general procedure: The cells were harvested and typically yielded 4 g/liter. The cell pellets were suspended (5 vol/g) in 50 mM NaH 2 PO 4 , pH 7.0, 0.1% Triton X-100, and 10 mM 2-mercaptoethanol. The suspension was passed through the French press at 14,000 psi. The cell lysate was centrifuged at 20,000 ϫ g for 30 min. The supernatant was treated with streptomycin sulfate to a final concentration of 1% (wt/vol), and the pellet was removed by centrifugation. The supernatant was incubated with Ni-NTA agarose resin (1 ml/g of cells; Qiagen, Valencia, CA) at 4°C for 1 h and then loaded into a column (2.5 ϫ 10 cm). The column was subsequently washed with 40 column vol of 50 mM NaH 2 PO 4 /800 mM NaCl/50 mM imidazole, pH 7.0/0.1% Triton X-100/10 mM 2-mercaptoethanol. The protein was eluted with 50 mM NaH 2 PO 4 /300 mM NaCl/125 mM imidazole, pH 7.0. Fractions containing protein were identified by using the Bradford assay. The fractions were pooled and concentrated to Ͻ10 ml, and then the imidazole was removed by Sephadex G-25 chromatography (200 ml, 2.5 ϫ 50 cm). ␤2 was stored in 50 mM Tris, 100 mM KCl, pH 7.6, 5% glycerol. ␣ was stored in 50 mM Tris, 100 mM KCl, 15 mM MgCl 2 , 5 mM DTT, pH 7.6, 5% glycerol. Protein yields of ␣ and ␤ were Ϸ2 mg and 15 mg/liter culture, respectively. The purity of ␣ and ␤ were analyzed on 10% SDS/ PAGE. Two more rapidly migrating bands detected by SDS/PAGE copurified with ␣. One of these impurities, identified by sequencing, is Arna, a hexameric E. coli protein with a subunit molecular mass of 74 kDa. The second impurity has not been identified.
Conversion of Human apo ␤2 to Holo ␤2. Stock solutions of (His) 6 -␤2 (2 ml, 2.5 mg/ml) were deoxygenated by 6 cycles of evacuation (for 3 ϫ 10 s) followed by argon flushing (2 min) on a Schlenk line. The deoxygenated ␤2 solution was brought into the glovebox (MBraun, Stratham, NH) and 5 eq of Fe(II) per ␤2 was added from a FeNH 4 SO 4 solution in buffer A (50 mM Tris/100 mM KCl, pH 7.6/5% glycerol). The resulting mixture was incubated at 4°C for 15 min. The protein was then removed from the glovebox, and 1 ml of O 2 saturated buffer A (50 mM Tris/100 mM KCl, pH 7.6, 5%) was added. Excess iron was removed by Sephadex G-25 chromatography (40 ml, 2.5 ϫ 20 cm).
